| Budget Amount *help |
¥25,480,000 (Direct Cost: ¥19,600,000、Indirect Cost: ¥5,880,000)
Fiscal Year 2009: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
Fiscal Year 2008: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
Fiscal Year 2007: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
|
|---|
| Research Abstract |
Feline infectious peritonitis (FIP) is caused by FIP virus (FIPV) belonging to coronaviridae. Once FIPV-infected cats develops the disease, it is highly-fatal because of the lack of specific anti-virus drugs and remedy. Therefore, FIP is the one of important infectious disease in small animal practice. A possible cellular receptor of feline coronavirus (FCoV) was identified to be the cell surface aminopeptidase N (APN)/CD13 but not fully understand in type I viruses. The blocking of virus-receptor binding might be a candidate for a therapeutic strategy. We focused on a competitive antagonist of APN, ubenimex, and evaluated its inhibitory effects on FIPV replication. No changes on cell growth and viability were detected in fcwf-4 cells cultivated under culture media containing ubenimex. The replication of the FIPV UCD-1 strain was inhibited on average 20-45% by the addition of ubenimex. However, dose dependency was not observed. On the other hand, the replication of the FIPV 79-1146 strain was significantly inhibited in a ubenimex's dose dependent manner. These results suggested that ubenimex shows potent inhibitory effects on type II FIPV. The toxicity of ubenimex was not detected in cats. In addition, It was possible to obtain blood concentration of ubenimex, which had shown potent inhibitory effect against viral growth in vitro, in cats. Because it was suggested that ubenimex would be a causal therapeutic for FIP caused by type II FIPV, an epidemiological survey was carried out to understand the type of harboring virus. This survey clarified high prevalence of FCoV infected cats and type II virus compared to the previous studies.
|
